TD Cowen Maintains Buy on BridgeBio Pharma, Lowers Price Target to $100

Benzinga · 2d ago
TD Cowen analyst Tyler Van Buren maintains BridgeBio Pharma (NASDAQ:BBIO) with a Buy and lowers the price target from $110 to $100.